Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099895 | 0.90 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1FKBP1AMEN1KMT2A | |
| SCHEMBL7639787 | 0.85 | GFER (0.48) | ALDH1A1L3MBTL1FKBP1AKDM4E | |
| SCHEMBL13841024 | 0.85 | PLAAT3 (0.51) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL11243649 | 0.84 | L3MBTL1 (0.57) | ALDH1A1L3MBTL1FKBP1ARAB9AUSP5 | |
| SCHEMBL2625210 | 0.82 | FFAR1 (0.51) | ALDH1A1L3MBTL1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL879572 | 0.82 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1FKBP1ARAB9AUSP5 | |
| SCHEMBL1509248 | 0.82 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1FKBP1ARAB9AUSP5 | |
| SCHEMBL19658332 | 0.82 | ALDH1A1 (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL106904 | 0.82 | ESR1 (0.50) | ALDH1A1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL28675816 | 0.81 | FFAR1 (0.46) | EPHX1KMT2AFFAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MONASH UNIVERSITY (AU) | 2023-10-05 | — | — | US | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885L3MBTL1 3548/4885FKBP1A 2072/4885 |
| US-20230312577-A1 | DUAL KINASE-BROMODOMAIN INHIBITORS | MAP2K2, BRPF3, BRDT | ALDH1A1 4173/4885L3MBTL1 2295/4885FKBP1A 2468/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ALDH1A1 72/4885L3MBTL1 3548/4885FKBP1A 2072/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | ALDH1A1 1860/4885L3MBTL1 4698/4885FKBP1A 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.